Amazon Biotech Retains Investor Relations Counsel for Clinical Trials of HIV Treatment

Amazon Biotech, Inc. (AMZB), a pharmaceutical company developing a potential immunomodulator drug for HIV treatment, has announced its retention of ROI Group Associates, Inc. as its investor relations counsel, marking a significant step as the company prepares to initiate U.S.-based clinical trials. The appointment of ROI Group Associates comes as Amazon Biotech seeks to enhance its immune response system using the proprietary formula AMZ 0026, comprised of a compilation of herbs. This move reflects the company's commitment to using a novel all-natural approach to treat HIV/AIDS, a disease that affects millions worldwide.

Key Takeaways:

• Amazon Biotech, Inc. (AMZB) has retained ROI Group Associates, Inc. as its investor relations counsel to facilitate a disciplined investor outreach program.
• The appointment is significant as Amazon Biotech prepares to initiate U.S.-based clinical trials of its potential immunomodulator drug for HIV treatment.
• The company is utilizing a proprietary formula, AMZ 0026, composed of herbs to enhance the immune response system.
• ROI Group Associates has extensive experience representing companies developing drug candidates for the treatment of HIV/AIDS.
• The company's CEO, Angelo Chinnici, MD, highlighted the importance of a growth-oriented approach in retaining ROI Group Associates.

Statistics:

• Amazon Biotech, Inc. (AMZB) is developing a potential immunomodulator drug for HIV treatment.
• The company is preparing to initiate U.S.-based clinical trials.
• ROI Group Associates has extensive experience in representing companies in the HIV field.
• The company's proprietary formula, AMZ 0026, is composed of herbs.

Sources:

• Amazon Biotech, Inc. (no date given)
• ROI Group Associates, Inc. (no date given)
• Health & Medicine Week editors, Copyright 2005, Health & Medicine Week via NewsRx.com.